Patents by Inventor William A. Gaarde

William A. Gaarde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
    Patent number: 6221850
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. The invention is thus directed to compositions for modulating, diagnostic methods for detecting, and therapeutic methods for inhibiting, the hyperproliferation of cells and formation, development and maintenance of tumors.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: April 24, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Nicholas Dean, Brett P. Monia, Pamela Scott Nero, William A. Gaarde
  • Antisense modulation of MEKK1 expression
    Patent number: 6168950
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK1. Methods of using these compounds for modulation of MEKK1 expression and for treatment of diseases associated with expression of MEKK1 are provided.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: January 2, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, William Gaarde, Donna T. Ward, Lex M. Cowsert
  • Antisense modulation of P38 mitogen activated protein kinase expression
    Patent number: 6140124
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of expression of a gene encoding a p38 mitogen-activated protein kinase (p38 MAPK) are provided. Methods for the treatment and diagnosis of diseases or conditions associated with aberrant expression of one or more p38 MAPKs are also provided.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: October 31, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, William A. Gaarde, Pamela S. Nero, Robert McKay
  • Antisense inhibition of focal adhesion kinase expression
    Patent number: 6133031
    Abstract: Compounds, compositions and methods are provided for inhibiting FAK mediated signaling. The compositions comprise antisense compounds targeted to nucleic acids encoding FAK. Methods of using these antisense compounds for inhibition of FAK expression and for treatment of diseases, particularly cancers, associated with overexpression or constitutive activation of FAK are provided.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: October 17, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, William A. Gaarde
  • Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
    Patent number: 6133246
    Abstract: Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are provided. Oligonucleotide are herein provided which are specifically hybridizable with nucleic acids encoding JNK1, JNK2 and JNK3, as well as other JNK proteins and specific isoforms thereof. Methods of treating animals suffering from diseases or disorders amenable to therapeutic intervention by modulating the expression of one or more JNK proteins with such oligonucleotide are also provided. Methods for the treatment and diagnosis of diseases or disorders associated with aberrant expression of one or more JNK proteins are also provided. Methods for inducing apoptosis and for treating diseases or conditions associated with a reduction in apoptosis are also provided.
    Type: Grant
    Filed: April 7, 1999
    Date of Patent: October 17, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Nicholas Dean, Brett P. Monia, Pamela S. Nero, William A. Gaarde
  • Antisense modulation of MEKK5 expression
    Patent number: 6080546
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK5. Methods of using these compounds for modulation of MEKK5 expression and for treatment of diseases associated with expression of MEKK5 are provided.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: June 27, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, William Gaarde, Lex M. Cowsert